Clinical trial of Grafix for treatment of chronic diabetic foot ulcers accepted for presentation at SAWC

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that its multi-center, randomized, controlled clinical trial evaluating the safety and effectiveness of Grafix^® for the treatment of chronic diabetic foot ulcers has been accepted for podium presentation at the upcoming Symposium on Advanced Wound Care (SAWC) in Las Vegas on Friday, September 27, 2013. Dr. Larry Lavery, Principal Investigator and Professor of Plastic Surgery at the University of Texas Southwestern Medical Center, will discuss the primary and secondary endpoints as well as additional key safety data from the trial.

In August, Osiris reported that the trial had reached the pre-specified stopping rules for overwhelming efficacy. 62% of patients receiving Grafix achieved complete wound closure compared to only 21% (p<0.0001) of patients receiving conventional treatment. Additionally, the trial demonstrated that Grafix closed wounds faster and required fewer treatments, with fewer adverse events than standard treatment.

The 26^th Symposium on Advanced Wound Care Conference is held from September 27^th to 29^th. The meeting is the largest wound care conference in the country and is the official conference of the Association for the Advancement of Wound Care (AAWC).